NULL

NULL

Abstract Background: Diabetes is a metabolic disorder characterized by hyperglycemia, resulting from defects in insulin secretion, insulin action, or both. Resistin is described as a potential factor in obesity mediated insulin resistance and type 2 diabetes mellitus. Aim: To evaluate the relationship of resistin levels with estimated glomerular filtration rate (e GFR) and albuminuria in type 2 diabetic patients and to elucidate the role of resistin as an early biomarker for early detection of diabetic kidney disease. Patients and methods: The study included 70 patients with type 2 diabetes mellitus, as well as 18 healthy participants as a control group who were age and sex matched with the patients. Serum resistin levels were assessed using an ELISA kit measured in ng/ml, albumin/creatinine ratio (ACR), eGFR by MDRD formula, and glycated hemoglobin (HbA1C). Results: There was a significant positive correlation between serum resistin level and both HbA1C and ACR but a significant negative correlation with eGFR. Conclusion: There was a significant increased level of HbA1C, resistin, and ACR (mg/g), whereas there was decreased level of eGFR in the patient group compared with the control group (P 0.001).

Abstract Background: Diabetes is a metabolic disorder characterized by hyperglycemia, resulting from defects in insulin secretion, insulin action, or both. Resistin is described as a potential factor in obesity mediated insulin resistance and type 2 diabetes mellitus. Aim: To evaluate the relationship of resistin levels with estimated glomerular filtration rate (e GFR) and albuminuria in type 2 diabetic patients and to elucidate the role of resistin as an early biomarker for early detection of diabetic kidney disease. Patients and methods: The study included 70 patients with type 2 diabetes mellitus, as well as 18 healthy participants as a control group who were age and sex matched with the patients. Serum resistin levels were assessed using an ELISA kit measured in ng/ml, albumin/creatinine ratio (ACR), eGFR by MDRD formula, and glycated hemoglobin (HbA1C). Results: There was a significant positive correlation between serum resistin level and both HbA1C and ACR but a significant negative correlation with eGFR. Conclusion: There was a significant increased level of HbA1C, resistin, and ACR (mg/g), whereas there was decreased level of eGFR in the patient group compared with the control group (P 0.001).

Abstract Aim: was to identify the prevalence and risk factors of vascular access failure among hemodialysis patients. Patients and method: A descriptive exploratory research design was utilized. This study was conducted in dialysis unit at Assiut University Hospital. The study sample consisted of 200 consecutive adult patients attended to dialysis unit at Assiut University Hospital within a period of 6 months their age ranged from 20 to 65 with mean age (40.76±13.24) years. Tools: Tool 1: Patient interview questionnaire sheet. Tool 2: Risk factors and causes of vascular access failure. Results: Incidence of vascular access failure among hemodialysis patients at Assuit University Hospital in over six month was (34.5%). Their age ranged from 40-65 year. Aging, diabetes, obesity, and infection were the major risk factors for vascular access failure. Conclusion: There was statistical significant relationship were found between the vascular access failure and duration of dialysis. Recommendation: Simple illustrated guidelines about vascular access and risk factors for failure should be available for patients in all dialysis units.

Abstract Aim: was to identify the prevalence and risk factors of vascular access failure among hemodialysis patients. Patients and method: A descriptive exploratory research design was utilized. This study was conducted in dialysis unit at Assiut University Hospital. The study sample consisted of 200 consecutive adult patients attended to dialysis unit at Assiut University Hospital within a period of 6 months their age ranged from 20 to 65 with mean age (40.76±13.24) years. Tools: Tool 1: Patient interview questionnaire sheet. Tool 2: Risk factors and causes of vascular access failure. Results: Incidence of vascular access failure among hemodialysis patients at Assuit University Hospital in over six month was (34.5%). Their age ranged from 40-65 year. Aging, diabetes, obesity, and infection were the major risk factors for vascular access failure. Conclusion: There was statistical significant relationship were found between the vascular access failure and duration of dialysis. Recommendation: Simple illustrated guidelines about vascular access and risk factors for failure should be available for patients in all dialysis units.

Abstract Aim: was to identify the prevalence and risk factors of vascular access failure among hemodialysis patients. Patients and method: A descriptive exploratory research design was utilized. This study was conducted in dialysis unit at Assiut University Hospital. The study sample consisted of 200 consecutive adult patients attended to dialysis unit at Assiut University Hospital within a period of 6 months their age ranged from 20 to 65 with mean age (40.76±13.24) years. Tools: Tool 1: Patient interview questionnaire sheet. Tool 2: Risk factors and causes of vascular access failure. Results: Incidence of vascular access failure among hemodialysis patients at Assuit University Hospital in over six month was (34.5%). Their age ranged from 40-65 year. Aging, diabetes, obesity, and infection were the major risk factors for vascular access failure. Conclusion: There was statistical significant relationship were found between the vascular access failure and duration of dialysis. Recommendation: Simple illustrated guidelines about vascular access and risk factors for failure should be available for patients in all dialysis units.

Abstract Background: Defining new predictive biomarkers in diabetic kidney disease (DKD) would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term micro and or macro vascular complications. Adiponectin (ADPN) has been variously associated with diabetic microvascular complications; however, no comprehensive clinical data exist examining the association between adipocytokines and the presence of these complications. Aim of study: we aimed to measure the plasma levels of adiponectin in patients with type 2 diabetes mellitus, to assess whether these levels vary with the different stages of DKD according to their e GFR and to evaluate its relation to their microvascular complications and glycemic control. Methods: This is a prospective observational study including 100 T2DM classified into two groups according to their albuminuria levels and estimated GFR. Participants subjected to thorough history taking and clinical examination. Serum level of ADPN was assessed in all patients. Results: Serum ADPN levels were significantly lower in T2DM patients with nephropathy (P = 0.001), while their levels were nonsignificantly higher in patients with non-proliferative retinopathy or neuropathy. Their levels were lowered with more advanced stages of DKD with nephropathy and the decrement was dependent on their severity (P0.001). Levels of ADPN with cutoff value of 22600 (μg/mL) had ability to diagnose microvascular complications in our diabetic patients with sensitivity (81%) and specificity (27%). Multivariate logistic regression analysis showed that the odds ratio for the presence of nephropathy in the lowest tertile of ADPN was 1.09 (95% CI; 11.45- 13.08, P= 0.06), therefore, ADPN was not an independent risk factor for diabetic nephropathy. However, its higher level was independently associated with increased odds for the presence of neuropathy in particular. Conclusions: ADPN plays a role in the pathogenesis of microvasculopathy in diabetic patients and help to identify high-risk patients and modulate the therapeutic potential in the revention of DKD.

Abstract Background: Defining new predictive biomarkers in diabetic kidney disease (DKD) would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term micro and or macro vascular complications. Adiponectin (ADPN) has been variously associated with diabetic microvascular complications; however, no comprehensive clinical data exist examining the association between adipocytokines and the presence of these complications. Aim of study: we aimed to measure the plasma levels of adiponectin in patients with type 2 diabetes mellitus, to assess whether these levels vary with the different stages of DKD according to their e GFR and to evaluate its relation to their microvascular complications and glycemic control. Methods: This is a prospective observational study including 100 T2DM classified into two groups according to their albuminuria levels and estimated GFR. Participants subjected to thorough history taking and clinical examination. Serum level of ADPN was assessed in all patients. Results: Serum ADPN levels were significantly lower in T2DM patients with nephropathy (P = 0.001), while their levels were nonsignificantly higher in patients with non-proliferative retinopathy or neuropathy. Their levels were lowered with more advanced stages of DKD with nephropathy and the decrement was dependent on their severity (P0.001). Levels of ADPN with cutoff value of 22600 (μg/mL) had ability to diagnose microvascular complications in our diabetic patients with sensitivity (81%) and specificity (27%). Multivariate logistic regression analysis showed that the odds ratio for the presence of nephropathy in the lowest tertile of ADPN was 1.09 (95% CI; 11.45- 13.08, P= 0.06), therefore, ADPN was not an independent risk factor for diabetic nephropathy. However, its higher level was independently associated with increased odds for the presence of neuropathy in particular. Conclusions: ADPN plays a role in the pathogenesis of microvasculopathy in diabetic patients and help to identify high-risk patients and modulate the therapeutic potential in the revention of DKD.

Abstract Background: Defining new predictive biomarkers in diabetic kidney disease (DKD) would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term micro and or macro vascular complications. Adiponectin (ADPN) has been variously associated with diabetic microvascular complications; however, no comprehensive clinical data exist examining the association between adipocytokines and the presence of these complications. Aim of study: we aimed to measure the plasma levels of adiponectin in patients with type 2 diabetes mellitus, to assess whether these levels vary with the different stages of DKD according to their e GFR and to evaluate its relation to their microvascular complications and glycemic control. Methods: This is a prospective observational study including 100 T2DM classified into two groups according to their albuminuria levels and estimated GFR. Participants subjected to thorough history taking and clinical examination. Serum level of ADPN was assessed in all patients. Results: Serum ADPN levels were significantly lower in T2DM patients with nephropathy (P = 0.001), while their levels were nonsignificantly higher in patients with non-proliferative retinopathy or neuropathy. Their levels were lowered with more advanced stages of DKD with nephropathy and the decrement was dependent on their severity (P0.001). Levels of ADPN with cutoff value of 22600 (μg/mL) had ability to diagnose microvascular complications in our diabetic patients with sensitivity (81%) and specificity (27%). Multivariate logistic regression analysis showed that the odds ratio for the presence of nephropathy in the lowest tertile of ADPN was 1.09 (95% CI; 11.45- 13.08, P= 0.06), therefore, ADPN was not an independent risk factor for diabetic nephropathy. However, its higher level was independently associated with increased odds for the presence of neuropathy in particular. Conclusions: ADPN plays a role in the pathogenesis of microvasculopathy in diabetic patients and help to identify high-risk patients and modulate the therapeutic potential in the revention of DKD.